ES2156997T3 - Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1). - Google Patents
Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1).Info
- Publication number
- ES2156997T3 ES2156997T3 ES96924553T ES96924553T ES2156997T3 ES 2156997 T3 ES2156997 T3 ES 2156997T3 ES 96924553 T ES96924553 T ES 96924553T ES 96924553 T ES96924553 T ES 96924553T ES 2156997 T3 ES2156997 T3 ES 2156997T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- heptanoico
- calcica
- fluorophenil
- amorfo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title 2
- FJFKYJKLMACIHF-UHFFFAOYSA-N [C].NC1=CC=CC=C1 Chemical compound [C].NC1=CC=CC=C1 FJFKYJKLMACIHF-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 3
- 229960005370 atorvastatin Drugs 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US145395P | 1995-07-17 | 1995-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2156997T3 true ES2156997T3 (es) | 2001-08-01 |
Family
ID=21696097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96924553T Expired - Lifetime ES2156997T3 (es) | 1995-07-17 | 1996-07-16 | Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1). |
Country Status (37)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| IN191236B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6646133B1 (en) | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
| HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| DK1341785T3 (da) * | 2000-11-16 | 2009-01-26 | Teva Pharma | Hydrolyse af R (R*,R*)-2-(4-fluorphenyl)-beta.delta-dihydroxy-5 (1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrol-1-heptansyrester med calciumhydroxid |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156280A0 (en) | 2000-12-27 | 2004-01-04 | Ciba Sc Holding Ag | Crystalline forms of atorvastatin |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) * | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IN190564B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| PL367943A1 (en) * | 2001-06-29 | 2005-03-07 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| EP1572638A4 (en) | 2001-08-31 | 2010-05-05 | Morepen Lab Ltd | IMPROVED METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN CALCIUM SALT (2: 1) |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| ES2338530T3 (es) * | 2002-03-18 | 2010-05-10 | Biocon Limited | Inhibidores de hmg-coa reductasa amorfos del tamaño de particulas deseado. |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| WO2003099785A1 (en) * | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| EP1562583A1 (en) * | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
| US8367848B2 (en) | 2003-04-11 | 2013-02-05 | Lek Pharmaceuticals D.D. | Process for the preparation of amorphous calcium salt of atorvastatin |
| ES2323366T3 (es) | 2003-04-22 | 2009-07-14 | Biocon Limited | Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres. |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US7557238B2 (en) | 2003-09-18 | 2009-07-07 | Biocon Limited | Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| AU2004317570B2 (en) * | 2004-03-17 | 2011-01-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| WO2005105738A2 (en) | 2004-05-05 | 2005-11-10 | Pfizer Products Inc. | Salt forms of atorvastatin |
| WO2006008091A2 (en) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| CA2578722C (en) | 2004-08-27 | 2010-02-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
| JP2008514722A (ja) * | 2004-09-30 | 2008-05-08 | ドクター レディズ ラボラトリーズ リミテッド | 非結晶性アトルバスタチンカルシウム |
| TW200942516A (en) * | 2004-10-18 | 2009-10-16 | Teva Pharma | Processes for preparing amorphous atorvastatin hemi-calcium |
| BRPI0519996A2 (pt) * | 2004-10-28 | 2009-04-07 | Warner Lambert Co | processo para formar atorvastatina amorfa |
| CA2588216A1 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| CA2589537A1 (en) * | 2004-12-02 | 2006-06-08 | Stephen Craig Dyar | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| EP1877375A1 (en) * | 2006-03-01 | 2008-01-16 | Teva Pharmaceutical Industries Ltd | Process for preparing a crystalline form of atorvastatin hemi-calcium |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| US20100260851A1 (en) * | 2007-07-11 | 2010-10-14 | Actavis Group Ptc Ehf | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium |
| US20090124817A1 (en) * | 2007-11-09 | 2009-05-14 | The Industry & Academic Cooperation In Chungnam National University | Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2010066846A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Method for the isolation of atorvastatin |
| WO2010069593A1 (en) | 2008-12-19 | 2010-06-24 | Krka, D. D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| ES2167587T3 (es) | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
-
1996
- 1996-07-03 HR HR960312A patent/HRP960312B1/xx not_active IP Right Cessation
- 1996-07-16 NZ NZ313008A patent/NZ313008A/xx not_active IP Right Cessation
- 1996-07-16 CN CN96195631A patent/CN1087289C/zh not_active Expired - Lifetime
- 1996-07-16 EE EE9700369A patent/EE03605B1/xx unknown
- 1996-07-16 IL IL12216196A patent/IL122161A/xx not_active IP Right Cessation
- 1996-07-16 BR BR9609714A patent/BR9609714A/pt not_active Application Discontinuation
- 1996-07-16 JP JP50681497A patent/JP4064459B2/ja not_active Expired - Lifetime
- 1996-07-16 SI SI9630284T patent/SI0839132T1/xx unknown
- 1996-07-16 EP EP96924553A patent/EP0839132B1/en not_active Revoked
- 1996-07-16 IN IN1579DE1996 patent/IN185276B/en unknown
- 1996-07-16 PL PL324463A patent/PL191017B1/pl unknown
- 1996-07-16 SK SK58-98A patent/SK283204B6/sk not_active IP Right Cessation
- 1996-07-16 DE DE69611999T patent/DE69611999T2/de not_active Revoked
- 1996-07-16 KR KR10-1998-0700348A patent/KR100400805B1/ko not_active Expired - Lifetime
- 1996-07-16 UA UA98020823A patent/UA50743C2/uk unknown
- 1996-07-16 RO RO98-00060A patent/RO120069B1/ro unknown
- 1996-07-16 PT PT96924553T patent/PT839132E/pt unknown
- 1996-07-16 GE GEAP19964149A patent/GEP20002027B/en unknown
- 1996-07-16 ES ES96924553T patent/ES2156997T3/es not_active Expired - Lifetime
- 1996-07-16 CZ CZ1998122A patent/CZ289421B6/cs not_active IP Right Cessation
- 1996-07-16 EA EA199800128A patent/EA000625B1/ru not_active IP Right Cessation
- 1996-07-16 CA CA002220455A patent/CA2220455C/en not_active Expired - Lifetime
- 1996-07-16 MX MX9708959A patent/MX9708959A/es unknown
- 1996-07-16 AT AT96924553T patent/ATE199542T1/de not_active IP Right Cessation
- 1996-07-16 HU HU9903017A patent/HU220343B/hu unknown
- 1996-07-16 AR ARP960103599A patent/AR002849A1/es not_active Application Discontinuation
- 1996-07-16 AU AU64978/96A patent/AU700794B2/en not_active Expired
- 1996-07-16 WO PCT/US1996/011807 patent/WO1997003960A1/en not_active Application Discontinuation
- 1996-07-16 DK DK96924553T patent/DK0839132T5/da active
- 1996-07-17 PE PE1996000541A patent/PE1698A1/es not_active IP Right Cessation
- 1996-07-17 ZA ZA9606043A patent/ZA966043B/xx unknown
- 1996-07-17 UY UY24286A patent/UY24286A1/es not_active IP Right Cessation
- 1996-07-17 CO CO96037512A patent/CO4700441A1/es unknown
-
1998
- 1998-01-14 BG BG102188A patent/BG63631B1/bg unknown
- 1998-01-16 NO NO980209A patent/NO309322B1/no unknown
-
2000
- 2000-09-07 US US09/657,469 patent/US6274740B1/en not_active Expired - Lifetime
-
2001
- 2001-05-15 GR GR20010400710T patent/GR3035859T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2156997T3 (es) | Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1). | |
| GEP20012580B (en) | Substituted 4-Hydroxy-Phenylalcanoic Acid Derivatives With Agonist Activity to PPAR-Gamma, Methods for Their Production, Pharmaceutical Conposition and Methods for Treatment | |
| BG102186A (en) | Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin) | |
| EE200200293A (et) | Meetod amorfse atorvastatiini valmistamiseks | |
| ES2167306T3 (es) | Acido (r-(r*,r*))-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4((fenilamino)-carbonil)-1h-pirrol-1-heptanoico, su forma de lactona y sales derivadas. | |
| RU95114376A (ru) | Нитроэфиры, обладающие фармакологической активностью, и способ их получения | |
| FI20011852A7 (fi) | Menetelmä fluoksetiinia tai sen happoadditiosuolaa sisältävän dispergoituvan tabletin valmistamiseksi | |
| AU8772691A (en) | New compounds | |
| UY24285A1 (es) | Procedimiento para la preparación de ácido cristalino | |
| PT100234A (pt) | Novos esteres de alcoois aminados biciclicos e triciclicos, processo para a sua preparacao | |
| EA199800230A1 (ru) | Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты) | |
| RU94045268A (ru) | Способ получения 1-(алкоксиметил)пиррольных соединений | |
| NZ511503A (en) | Manufacture of clevidipine by reacting an inorganic salt of a carboxylic acid with choromethyl butyrate | |
| EA199800280A1 (ru) | Новые производные 5-0-дезозаминил-6-0-метилэритронолида а, способ их получения и их использование при получении биологически активных продуктов | |
| AU4495793A (en) | 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds and process for the manufacture of insecticidal, 2-aryl-1-(alkoxymethyl)-4-halo-5-(trifluoromethyl) pyrroles | |
| ES2089993T3 (es) | Procedimiento y productos intermedios para la preparacion de clorhidrato de terazosina dihidrato. | |
| AR002306A1 (es) | Procedimiento mejorado para la preparacion de una sal de 5-(alcoximetil)piridina-2,3-dicarboxilato | |
| JPS5681557A (en) | Preparation of optically active alpha-methyl-beta- mercaptopropionic acid derivative | |
| ID16017A (id) | Proses yang dimanfaatkan untuk memproduksi asam organik | |
| ECSP961822A (es) | NUEVO PROCESO PARA LA PRODUCCION DE UNA SAL ACIDA CALCICA AMORFA [R- (R*, R*)]-2-(4- FLUOROFENILO)-ß, 6- DIHIDROXI- 5 - (1- METILETILO)- 3 - FENILO -4-[(FENILAMINO) CARBONILO] - 1H- PIRROL - 1 - ACIDO HEPTANOICO | |
| MX9704257A (es) | Proceso para la preparacion de compuestos de 5-(alcoximetil) -2,3-piridinodicarboximida. | |
| HUT42083A (en) | Herbicides containing azolides of kynolin-8-carbonic acid and process for production of the active substance | |
| JPS5726658A (en) | 4r -4- 3-substituted carboxy-3-diazo-2-oxopropyl -2- azetidinone derivative and its preparation | |
| SV1998000012A (es) | Metodo para la preparacion de (1s, 4r) -1-azabiciclo [2.2.1] heptano-3- uno y (1r,4s), 1-azabiciclo [2.2.1] heptano-3-uno. | |
| BR9402825A (pt) | Amidas de pirazol carbóxi ácidos, acaracidas e inseticidas, processo para sua produção e composições tendo atividade acaricida e inseticida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 839132 Country of ref document: ES |